drugset / Trial / NCT05779579
Study of HS-10517 in Chinese Adult Participants
RandomizedParallel-groupDouble-blindOther
Summary
A Phase I/II, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and primary efficacy of HS-10517 in Chinese adult participants.
Timeline
- Start
- 2023-02-01
- Primary completion
- 2023-05-31
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10517 | Unknown | — | — |
| Background | Ritonavir | Other / unclassified | — | — |